Trial Outcome
Jazz Pharmaceuticals (NASDAQ:JAZZ) announced on 13 June 2026 that its lung‑cancer drug Zepzelca did not meet the primary endpoint of improving overall survival in a late‑stage confirmatory study, a result that could affect the drug’s current regulatory standing.
Survival Data
The trial evaluated Zepzelca as a single agent and in combination with chemotherapy. Patients receiving Zepzelca alone experienced a median overall survival of 8.7 months. Those receiving Zepzelca together with chemotherapy had a median overall survival of 10.9 months, compared with 10.7 months for patients in the control arm.
Drug Profile
Zepzelca holds accelerated approval from the U.S. Food and Drug Administration for use as a second‑line therapy in advanced small cell lung cancer, an aggressive disease that frequently spreads to bone marrow and other organs.
Regulatory Status and Next Steps
The company has transmitted the trial results to the FDA and will discuss next steps concerning any post‑marketing requirements for the drug’s second‑line indication.
Additional Information
The article was generated with AI assistance and reviewed by an editor. © Reuters.